In a nutshell This trial is looking at the effectiveness, safety, and tolerability of ladiratuzumab vedotin (LV) in patients with advanced solid tumors, including prostate cancer. The main outcome to be measured in this trial is the response rate to the new drug. The details Advanced tumors have spread from the organ where they originated. These...
Read More
In a nutshell This trial is looking at the effectiveness, safety, and tolerability of ladiratuzumab vedotin (LV) in patients with advanced solid tumors, including melanoma. The main outcome to be measured in this trial is the response rate to the new drug. The details Advanced tumors have spread from the organ where they originated....
Read More
In a nutshell This trial is aiming to assess the effectiveness and safety of a new drug (CIN-107) in patients with treatment-resistant hypertension (rHTN). The main outcome that will be measured is the change in blood pressure over a time-frame of 12-weeks. This trial is being carried out in the United States. The details Resistant...
Read More
In a nutshell This trial is looking to recruit patients with diabetic macular edema (DME) to trial a new gene therapy, ADVM-022. This trial is aiming to measure the time it takes for DME to worsen. This trial is being carried out in Puerto Rico and the United States. The details DME affects up to 10% of people with diabetes and is caused by fluid...
Read More
In a nutshell This trial is being carried out to examine the effectiveness of LY3016859 for diabetic neuropathic pain (DNP; pain caused by damage to the nerves). The main outcome to be measured is a change in pain intensity. This study is being carried out in Puerto Rico and the United States. The details Uncontrolled diabetes can lead...
Read More
In a nutshell This trial is aiming to examine the effectiveness of zanubrutinib (Brukinsa) in combination with rituximab (Rituxan) to treat chronic lymphocytic leukemia (CLL). The main outcome to be measured is the number of patients who achieve the reduction or disappearance of their CLL. This trial is being carried out in Texas, the...
Read More
In a nutshell This study is looking to recruit patients with prostate cancer (PC) spread to the bone to trial internal and external radiotherapy. The main outcome that will be measured is the length of time until patients need androgen deprivation therapy (ADT). This trial will be carried out in Utah, the United States. The details PC...
Read More
In a nutshell This study will evaluate a three-drug regimen for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). The primary outcomes are how many patients respond to treatment or have a complete response (cancer no longer detectable). The study will take place in the United States. The details B-cell...
Read More
In a nutshell This study will evaluate a three-drug regimen for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). The primary outcomes are how many patients respond to treatment or have a complete response (cancer no longer detectable). The study will take place in the United States. The details B-cell...
Read More
In a nutshell This study will evaluate the antibody therapy odronextamab for patients with relapsed B-cell non-Hodgkin lymphoma (NHL). The primary outcomes will be how many patients respond to treatment, and how many have a complete response (cancer no longer detectable). The details For B-cell NHL which has relapsed (returned) after...
Read More
In a nutshell This trial is looking to examine the effectiveness of carboplatin (Paraplatin), paclitaxel (Taxol), and ramucirumab (Cyramza) in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC) that is progressive after maintenance therapy. The main outcome that is to be measured is the response of the...
Read More
In a nutshell This study will evaluate the best dose of idelalisib (Zydelig) for patients with relapsed follicular lymphoma (FL). The primary outcomes are overall response and side effects. The details FL is a slow-growing cancer of B-cells, a type of white blood cell. Idelalisib is a medication that inhibits certain proteins involved in...
Read More
